Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hecht, Randy
PanNEN, NCT05746182: Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms	Recruiting	N/A	300	US	Hereditary Cancer Panel, University of California, San Francisco's (UCSF) Expanded Hereditary Cancer Panel, Germline Testing	University of California, San Francisco, University of California Pancreatic Cancer Consortium (UCPCC)	Pancreatic Neuroendocrine Neoplasm	12/25	12/25
Cherian, Bindu
RASolute 302, NCT06625320: Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)	Recruiting	3	460	US	RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin	Revolution Medicines, Inc.	Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	06/26	12/27
BOLD-100-001, NCT04421820 / 2022-003079-41: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours	Recruiting	1/2	220	Europe, Canada, US, RoW	BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)	Bold Therapeutics, Inc., Bold Therapeutics, Inc. (Bold)	Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma	06/26	09/26
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors	Recruiting	1	64	US	RBS2418, Pembrolizumab	Riboscience, LLC., Oncobay Clinical, Inc	Advanced Cancer	09/25	10/25
Etheridge, Lia
No trials found
Davis, Sa-Heim
No trials found